Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Operating Expenses (2021 - 2025)

Historic Other Operating Expenses for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $110196.0.

  • InMed Pharmaceuticals' Other Operating Expenses rose 40821.38% to $110196.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $279619.0, marking a year-over-year increase of 57967.67%. This contributed to the annual value of $191106.0 for FY2025, which is 16698.61% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Other Operating Expenses of $110196.0 as of Q3 2025, which was up 40821.38% from $18409.0 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Other Operating Expenses ranged from a high of $145839.0 in Q3 2022 and a low of -$8.8 million during Q2 2022
  • Moreover, its 5-year median value for Other Operating Expenses was $21683.0 (2024), whereas its average is -$925946.8.
  • Over the last 5 years, InMed Pharmaceuticals' Other Operating Expenses had its largest YoY gain of 44838.82% in 2024, and its largest YoY loss of 13360.27% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Other Operating Expenses stood at -$4.2 million in 2021, then soared by 99.45% to -$23286.0 in 2022, then dropped by 24.71% to -$29040.0 in 2023, then soared by 405.6% to $88746.0 in 2024, then increased by 24.17% to $110196.0 in 2025.
  • Its Other Operating Expenses was $110196.0 in Q3 2025, compared to $18409.0 in Q2 2025 and $62268.0 in Q1 2025.